Breaking Down Racial Disparities in Cancer Care: The Affordable Care Act

Breaking Down Racial Disparities in Cancer Care: The Affordable Care Act Posted By:
...

Racial disparities are well known to exist in cancer care and outcomes. Several barriers exist including access to care, cultural biases about healthcare and providers, and cost of medical care. At the American Society of Clinical Oncology meeting in early June 2019, a plenary session was dedicated to the presentation of research looking at the impact of Medicaid expansion as part of the Affordable Care Act (ACA) and its relationship to cancer care and outcomes across different racial groups.

The ACA expanded Medicaid and provided subsidies for purchasing private health insurance in several states. The aim was to improve equity in access to healthcare as well as outcomes. Using the Flatiron Health electronic medical database, researchers gathered data between January 1, 2011 and December 31, 2018 on patients with several different solid tumor types: lung cancer, breast cancer, and colon cancer, as well as several others. The main outcome for measurement was "timely treatment," which was defined as starting first-line treatment for their cancer within 30 days of the original diagnosis.

The study included over 34,000 patients with a median age of 57, 12% of which were African Americans. In the pre-ACA dates, African Americans were 4.9% less likely than whites to receive timely treatment. Once the ACA was implemented, regardless of race, there was a trend toward improvement in time to treatment. In the time period post-ACA, there was a 6.9% increase in timely treatments for African American patients with cancer, and 1.8% for white patients with cancer.

In conclusion, the ACA—including Medicaid expansion and subsidies for private insurance—improved access to care and reduced racial disparities in cancer care.

Reference
  • Adamson BJS, Cohen AB, Estevez M, et al. Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment. J Clin Oncol. 2019;37:18(suppl). Abstract LBA1.

Share

Filed under: Oncology/Hematology

Related
BTK Inhibitors in CLL/SLL and MCL: The Latest Guidance and Evidence for the Clinic

BTK Inhibitors in CLL/SLL and MCL: The Latest Guid ...

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) a ...

Filed under: Oncology/Hematology, NPs & PAs


Continue Reading
Our Experiences With Mirvetuximab Soravtansine in Advanced Ovarian Cancer

Our Experiences With Mirvetuximab Soravtansine in ...

In this Exchange post, Sarah Hayward, PharmD, BCOP, and Amy Ly Indorf, PharmD, BCOP, discuss their p ...

Filed under: Women's Health, Oncology/Hematology, NPs & PAs


Continue Reading
My Experience Managing Key Adverse Events With Oral Targeted Therapy for High-Risk Early Breast Cancer

My Experience Managing Key Adverse Events With Ora ...

Recent years have seen the approval of oral targeted therapy options for the treatment of high-risk ...

Filed under: Oncology/Hematology, NPs & PAs


Continue Reading
Maximizing Benefit With the Expanding Options for Gastric Cancer: Expert Answers to Frequently Asked Questions

Maximizing Benefit With the Expanding Options for ...

In this post, James M. Cleary, MD, PhD, answers key questions from attendees of a webinar developed ...

Filed under: Oncology/Hematology, NPs & PAs


Continue Reading
Inpatient and Outpatient Management of Immune-Related Adverse Events

Inpatient and Outpatient Management of Immune-Rela ...

Immune checkpoint inhibitors (ICIs) carry the unique risk of a highly unpredictable class of toxicit ...

Filed under: Oncology/Hematology, NPs & PAs


Continue Reading
Counseling Patients and Caregivers on Immune-Related Adverse Events

Counseling Patients and Caregivers on Immune-Relat ...

In this commentary, Alexa Basilio, PharmD, BCOP, and Jordan McPherson, PharmD, MS, BCOP, discuss imp ...

Filed under: Oncology/Hematology, NPs & PAs


Continue Reading